Cargando…

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Jisoo A., Dore, Gregory J., Hajarizadeh, Behzad, Alavi, Maryam, Valerio, Heather, Grebely, Jason, Guy, Rebecca, Gray, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445464/
https://www.ncbi.nlm.nih.gov/pubmed/34529711
http://dx.doi.org/10.1371/journal.pone.0257369
_version_ 1784568665004310528
author Kwon, Jisoo A.
Dore, Gregory J.
Hajarizadeh, Behzad
Alavi, Maryam
Valerio, Heather
Grebely, Jason
Guy, Rebecca
Gray, Richard T.
author_facet Kwon, Jisoo A.
Dore, Gregory J.
Hajarizadeh, Behzad
Alavi, Maryam
Valerio, Heather
Grebely, Jason
Guy, Rebecca
Gray, Richard T.
author_sort Kwon, Jisoo A.
collection PubMed
description Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis-cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030.
format Online
Article
Text
id pubmed-8445464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84454642021-09-17 Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications Kwon, Jisoo A. Dore, Gregory J. Hajarizadeh, Behzad Alavi, Maryam Valerio, Heather Grebely, Jason Guy, Rebecca Gray, Richard T. PLoS One Research Article Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis-cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030. Public Library of Science 2021-09-16 /pmc/articles/PMC8445464/ /pubmed/34529711 http://dx.doi.org/10.1371/journal.pone.0257369 Text en © 2021 Kwon et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kwon, Jisoo A.
Dore, Gregory J.
Hajarizadeh, Behzad
Alavi, Maryam
Valerio, Heather
Grebely, Jason
Guy, Rebecca
Gray, Richard T.
Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title_full Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title_fullStr Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title_full_unstemmed Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title_short Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
title_sort australia could miss the who hepatitis c virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445464/
https://www.ncbi.nlm.nih.gov/pubmed/34529711
http://dx.doi.org/10.1371/journal.pone.0257369
work_keys_str_mv AT kwonjisooa australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT doregregoryj australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT hajarizadehbehzad australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT alavimaryam australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT valerioheather australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT grebelyjason australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT guyrebecca australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications
AT grayrichardt australiacouldmissthewhohepatitiscviruseliminationtargetsduetodecliningtreatmentuptakeandongoingburdenofadvancedliverdiseasecomplications